Cultivators, wholesalers, and pharmacies in medical cannabis markets face the same problem: a wrong cultivar or supplier decision costs money and erodes patient trust — and often the real problem starts earlier, in not knowing what patients actually want or need.
Jan Wegner Consulting is a founder-led advisory practice built on hands-on production experience — straight answers grounded in what's actually happening on the ground, not what's easiest to sell.
That means working directly in the details that matter at every step: cultivar selection, cultivation practices, post-harvest handling, portfolio management, and patient quality metrics.
Who This Is For
Get the cultivar and trial-design calls right the first time.
Supplier and genetics-source evaluation, checked on-site before you commit.
Product guidance grounded in what patients actually need, not just what's available.
Portfolio strategy and market entry guidance for building a presence in medical cannabis markets.
About
Jan Wegner brings over 20 years of hands-on experience, 13 of them in regulated cannabis markets — building genetics programs and cultivation strategy from the ground up, not from behind a desk.
Jan works in-facility, alongside cultivation and post-harvest teams around the globe.
Services
An ongoing advisory relationship built around the decisions that actually move a cultivation or portfolio strategy forward.
Delivered remotely, with on-location visits when the work calls for it.
Discuss a Project
Hands-on, in-facility genetics selection, done alongside your team through to post-harvest.
Genetics selected specifically for your operation, sourced through verified, compliant channels and evaluated on-site with your team. The more thorough path, with a longer lead time.
Selection from your operation's already-available genetics, evaluated with the same rigor. Faster turnaround for teams on a shorter timeline.
Subject to an existing project consultation agreement.
Discuss the ProgramWho We Work With
Trial design starts before the first seed goes in the ground — matching genetics to your specific facility, climate, and post-harvest capacity rather than picking off a catalog. That upfront match is what determines whether a cultivar performs the second time, not just the first.
Every supplier and genetics source gets evaluated on-site, not through paperwork or a supplier's own claims — so sourcing risk gets caught before it enters your inventory, not after a batch underperforms.
Product guidance built around what a patient population actually needs, cross-checked against what's realistic to source and supply within medical cannabis market regulations — not a generic catalog recommendation.
Entering a medical cannabis market means getting the genetics and the regulatory pathway right at the same time — miss either one and the other doesn't matter. Portfolio strategy and market entry guidance here covers both together.
Interested in a licensing or royalty-based market entry structure? That's a separate conversation — get in touch directly to discuss.
Contact
Every engagement starts with a conversation about what you're actually trying to solve.
